Key result
The 2017 focused update of the 2013 ACC/AHA guideline on heart failure provides new recommendations on prevention, biomarker uses, HFpEF, and comorbidities such as hypertension and iron deficiency.
Summarizes the 2017 focused update of the 2013 ACC/AHA guideline on heart failure, highlighting new recommendations for prevention, biomarkers, HFpEF, and comorbidities.
The 2017 focused update of the 2013 ACC/AHA guideline on heart failure contains new and important recommendations on prevention, novel biomarker uses, heart failure with preserved ejection fraction (HFpEF), and comorbidities such as hypertension, iron deficiency, and sleep-disordered breathing. Potential implications for management of acute decompensated heart failure will also be explored.
No takes yet. Share an insight, caveat, or question.
Haselhuhn et al. (2019) conducted a review in Heart failure. The 2017 focused update of the 2013 ACC/AHA guideline on heart failure provides new recommendations on prevention, biomarker uses, HFpEF, and comorbidities such as hypertension and iron deficiency.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: